Clinical trials: Esophagogastric Junction
Gastroesophageal Adenocarcinoma, Adenocarcinoma of the Distal Esophagus
Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma
This is an open-label, Phase II, single-stage study evaluating the use of panitumumab, paclitaxel, carboplatin and 5FU as an induction regimen in subjects with gastroesophageal adenocarcinoma.
- Conditions
- Gastroesophageal Adenocarcinoma, Adenocarcinoma of the Distal Esophagus, Adenocarcinomas of the Gastroesophageal Junction, Adenocarcinoma of the Proximal Stomach
- Trial name
- NCT01182610
- Testing
- Panitumumab, Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Accelerated Community Oncology Research Network
Adenocarcinoma of Esophagogastric Junction
Transhiatal/Transabdominal Approach Compare With Thoracoabdominal Approach for Siewert II Adenocarcinoma of Esophagogastric Junction
To compare transhiatal / transabdominal approach with thoracoabdominal approach for Siewert II adenocarcinoma of esophagogastric junction
- Trial name
- NCT04910789
- Testing
- transhiatal/transabdominal approach, thoracoabdominal approach
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Chinese PLA General Hospital
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
This phase I trial tests the safety, side effects and best dose of futibatinib with paclitaxel and ramucirumab for the treatment of patients with gastric, gastroesophageal junction or esophageal adenocarcinoma that has spread to…
- Conditions
- Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT07594548
- Testing
- Biospecimen Collection, Computed Tomography, Futibatinib
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Northwestern University
Stomach Neoplasms, Gastrointestinal Neoplasms
FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma
Patients with resectable adenocarcinoma of the stomach or the esophagogastric junction (II-III type by Siewert) without previous therapy will be treated with one of two chemotherapy combinations before and after surgery.
- Conditions
- Stomach Neoplasms, Gastrointestinal Neoplasms, Docetaxel, Oxaliplatin
- Trial name
- RusGCG-01 (NCT04393584)
- Testing
- Irinotecan, 5-FU, Leucovorin
- Where
- Russia
- Volunteers
- 538 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Colorectal Cancer (CRC), Gastric Cancer
A Study of SC-007 in Subjects With Advanced Cancer
This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC-007 and consists of Part A (dose regimen finding) in participants with CRC…
- Trial name
- NCT03253185
- Testing
- SC-007
- Where
- 7 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- AbbVie
Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy
Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
This study aims to compare the efficacy and safety of neoadjuvant apatinib combined with sintilimab and perioperative SOX chemotherapy versus neoadjuvant sintilimab combined with perioperative SOX chemotherapy in locally advanced…
- Conditions
- Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate
- Trial name
- NCT06925243
- Testing
- Neoadjuvant apatinib combined with sintilimab and perioperative SOX, Neoadjuvant sintilimab combined with perioperative SOX
- Where
- 4 sites in China
- Volunteers
- 682 people
- Sponsor
- Zuoyi Jiao
Gastric / Gastroesophageal Junction Adenocarcinoma
Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer
This study is to evaluate the efficacy and safety of chemotherapy combined with or without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction…
- Trial name
- NCT07132528
- Testing
- SOX plus PD-1 inhibitor, SOX Chemotherapy
- Volunteers
- 1,000 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
The goal of this study is to learn about of the research study drug, telomelysin (OBP-301), in combination with pembrolizumab in advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer.
- Conditions
- Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT06340711
- Testing
- OBP-301, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Weill Medical College of Cornell University
Adenocarcinoma of Stomach or Esophagogastric Junction
Efficacy of Cetuximab in Combination With Irinotecan and 5- FU/FA in Treatment of Metastatic Gastric Cancer
Based on the current promising results with irinotecan and cetuximab in patients with recurrent metastatic colorectal cancer, and the excellent results of Irinotecan and 5-FU in gastric cancer , the present clinical study to…
- Trial name
- GC-CIF-2005 (NCT01123811)
- Testing
- Cetuximab IF
- Where
- 10 sites in Germany
- Volunteers
- 45 people
- Sponsor
- Johannes Gutenberg University Mainz
Resectable Gastric and Gastroesophageal Junction Adenocarcinoma
Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.
In this clinical trial, patients with gastric and gastroesophageal junction adenocarcinoma will be included. Treatment with curative intent will be given with chemotherapy for 4 cycles with fluorouracil, oxaliplatin and…
- Trial name
- INTENSE (NCT03773367)
- Testing
- Fluorouracil, Oxaliplatin, Irinotecan
- Where
- 4 sites in Norway, Sweden
- Volunteers
- 60 people
- Sponsor
- Lund University Hospital
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Claudin 18.2 or CLDN18.2 is a protein found on cells in the digestive system. It is also found in some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors.
- Trial name
- NCT07673887
- Testing
- ASP2138, Pembrolizumab, Oxaliplatin
- Where
- 8 sites in United States, China and 2 more
- Volunteers
- 570 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Gastric Cancer, Metastatic
The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM
Gastric cancer (GC) with peritoneal metastasis has a poor prognosis and short survival. In recent years, heat intraperitoneal perfusion chemotherapy (HIPEC) has gained better efficacy in the treatment of peritoneal metastases of…
- Trial name
- NCT06427252
- Testing
- HIPEC, Systemic therapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Real-world Data (RWD) of Ramucirumab Plus Paclitaxel
Real World Data (RWD) obtained from real clinical sites is data obtained after administering a drug to patients with different characteristics in daily practice, and Real World Evidence (RWE) is established based on RWD.
- Trial name
- NCT04915807
- Testing
- Ramucirumab and paclitaxel, Taxane, irinotecan, or fluoropyrimidine-based single or combined chemotherapy
- Where
- 9 sites in South Korea
- Volunteers
- 222 people
- Sponsor
- Hallym University Medical Center
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens
This is a Phase II, open-label, single-arm, multicentre, study in China assessing the efficacy and safety of T-DXd in participants with HER2-expressing advanced gastric or GEJ adenocarcinoma who have received at least 2 prior…
- Trial name
- DG-06 (NCT04989816)
- Testing
- Trastuzumab Deruxtecan
- Where
- 24 sites in China
- Volunteers
- 95 people
- Sponsor
- AstraZeneca
HER2 Positive Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer
TAC T-cells for the Treatment of HER2-positive Solid Tumors
TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2).
- Trial name
- TACTIC-2 (NCT04727151)
- Testing
- TAC01-HER2, TAC01-HER2 plus pembrolizumab
- Where
- 11 sites in United States, Canada
- Volunteers
- 28 people
- Sponsor
- Triumvira Immunologics, Inc.
Gastroesophageal Junction Cancer
PET/MR-imaging to Differentiate Between Responders and Non-responders Receiving Preoperative Chemotherapy
The incidence of malignity in the gastroesophageal junction (GEJ) is rising in Denmark, 400 new cases annually 1. 60% of the patients with GEJ cancer have disseminated disease (M1-stage) at time of diagnosis and are consequently…
- Trial name
- NCT02433301
- Where
- Denmark
- Volunteers
- 23 people
- Sponsor
- Rikshospitalet University Hospital
Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
The purpose of this study is to evaluate the safety and efficacy of S-1 and Cisplatin compared to 5-FU and Cisplatin in treatment of patients with metastatic diffuse gastric and gastro-esophageal junction cancer previously…
- Trial name
- DIGEST (NCT01285557)
- Testing
- S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm), Fluorouracil/cisplatin (control arm)
- Where
- 87 sites in United States, Argentina and 18 more
- Volunteers
- 361 people
- Sponsor
- Taiho Oncology, Inc.
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
This randomized phase II trial studies how well giving irinotecan hydrochloride with or without alvocidib works in treating patients with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach
- Trial name
- NCT00991952
- Testing
- alvocidib, irinotecan hydrochloride, laboratory biomarker analysis
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer
5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
Patients with locally advanced resectable adenocarcinoma of the stomach or the esophagogastreal junction without previous therapy will be treated with one of two chemotherapy combinations before and after surgery.
- Trial name
- NCT01216644
- Testing
- 5-Fluorouracil, Leucovorin, Oxaliplatin
- Where
- Germany
- Volunteers
- 716 people
- Sponsor
- Krankenhaus Nordwest
Esophagus Adenocarcinoma, Esophagus Squamous Cell Carcinoma
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Esophageal cancer, which has a low 5-year overall survival rate for all stages (<20%) , is increasing in incidence. Previous studies have shown that the Hedgehog (Hh) and AKT signaling pathways are activated in a significant…
- Conditions
- Esophagus Adenocarcinoma, Esophagus Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT04018872
- Testing
- Itraconazole
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Dallas VA Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.